BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

806 related articles for article (PubMed ID: 22559260)

  • 21. A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study.
    Teeuwen K; Adriaenssens T; Van den Branden BJ; Henriques JP; Van der Schaaf RJ; Koolen JJ; Vermeersch PH; Bosschaert MA; Tijssen JG; Suttorp MJ
    Trials; 2012 Dec; 13():240. PubMed ID: 23241457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled PATENT-C first in human trial.
    Scheller B; Fontaine T; Mangner N; Hoffmann S; Bonaventura K; Clever YP; Chamie D; Costa R; Gershony G; Kelsch B; Kutschera M; Généreux P; Cremers B; Böhm M; Speck U; Abizaid A
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):51-9. PubMed ID: 26331782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
    de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions.
    Cortese B; Danzi GB; Pitì A; Severi S; Limbruno U
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):32-7. PubMed ID: 21413116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation.
    Kim BK; Kim JS; Oh C; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):705-14. PubMed ID: 21626042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stent strut coverage of titanium-nitride-oxide coated stent compared to paclitaxel-eluting stent in acute myocardial infarction: TITAX-OCT study.
    Lehtinen T; Airaksinen KE; Ylitalo A; Karjalainen PP
    Int J Cardiovasc Imaging; 2012 Dec; 28(8):1859-66. PubMed ID: 22362097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation.
    Ko YG; Kim DM; Cho JM; Choi SY; Yoon JH; Kim JS; Kim BK; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):715-23. PubMed ID: 21656060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    BMC Cardiovasc Disord; 2017 Jun; 17(1):168. PubMed ID: 28651572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study.
    Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B
    EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis.
    Nijhoff F; Stella PR; Troost MS; Belkacemi A; Nathoe HM; Voskuil M; Samim M; Doevendans PA; Agostoni P
    Clin Res Cardiol; 2016 May; 105(5):401-11. PubMed ID: 26541146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomography.
    Ikuta S; Kobuke K; Iwanaga Y; Nakauchi Y; Yamaji K; Miyazaki S
    Heart Vessels; 2014 May; 29(3):320-7. PubMed ID: 23793881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
    García-García HM; Garg S; Brugaletta S; Morocutti G; Ratner RE; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Nesto RW; Serruys PW;
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):455-65. PubMed ID: 21359834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxcel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study.
    Fischer D; Scheller B; Schäfer A; Klein G; Böhm M; Clever Y; Cremers B
    EuroIntervention; 2012 Aug; 8(4):450-5. PubMed ID: 22917728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results.
    Kim TH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2011 Jul; 27(6):875-81. PubMed ID: 20978851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries.
    Wöhrle J; Werner GS
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):793-9. PubMed ID: 22511572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological effect on drug distribution and vascular healing via paclitaxel-coated balloon technology in drug eluting stent restenosis swine model.
    Li Y; Tellez A; Rousselle SD; Dillon KN; Garza JA; Barry C; Granada JF
    Catheter Cardiovasc Interv; 2016 Jul; 88(1):89-98. PubMed ID: 26613810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.